ACOG

Alpha Cognition Inc. (ACOG) - 10-Q Summary for Period Ended September 30, 2024

Business Context and Reporting Period

Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, specifically Alzheimer's Disease (AD) and Traumatic Brain Injury (TBI). The reporting period covers the three and nine months ended September 30, 2024. The Company received FDA approval for its lead product, ZUNVEYL (benzgalantamine), for mild-to-moderate AD in July 2024. The Company is classified as a Smaller Reporting Company and an Emerging Growth Company. As of November 14, 2024, there were 15,531,282 common shares outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses for the nine months ended Sept 30, 2024, increased by 24% to $9.32 million compared to $7.52 million in the prior year period. This was driven by a 72% increase in General and Administrative (G&A) expenses to $6.44 million, largely due to financing fees ($354,791) and consulting fees ($2.57 million, including $2.27 million in shares issued for services). Conversely, R&D expenses decreased by 24% to $2.88 million due to lower product development costs following the NDA filing.
• Other Income/Expense: The Company recorded a significant gain of $174,930 from the change in fair value of the conversion feature liability and a gain of $416,806 from the change in fair value of warrant liabilities for the three-month period. Grant income increased significantly to $333,462 for the nine-month period compared to $32,757 in the prior year.
• Debt and Equity: In September 2024, the Company issued $4.545 million in convertible debentures. In the nine months ended Sept 30, 2024, the Company raised $3.73 million from private placement units and $4.55 million from convertible debentures.

Guidance, Outlook, and Risks

• Commercialization: The Company anticipates launching ZUNVEYL in Q1 2025. The Wholesale Acquisition Cost (WAC) is set at $649 per month. The focus is on building a long-term care commercial team.
• Subsequent Events (Post-Sept 30): On November 13, 2024, the Company completed a public offering of 8,695,653 shares at $5.75 per share, raising gross proceeds of approximately $50 million. This triggered the automatic conversion of the $4.545 million convertible debentures into 801,413 common shares. The Company also completed a 1-for-25 reverse stock split on November 5, 2024.
• Liquidity and Going Concern: As of September 30, 2024, management noted a material uncertainty regarding the Company's ability to continue as a going concern without additional financing. However, following the November 2024 public offering, management believes it has sufficient working capital to meet liabilities for the next 12 months.
• Risks: Risks include the inability to raise additional capital on acceptable terms, the success of commercialization efforts for ZUNVEYL, and the volatility of warrant and derivative liabilities which significantly impact reported net loss.

Key Investor Verification Points

• Post-Period Financing: Verify the final net proceeds and share count impact from the November 13, 2024, public offering and the subsequent conversion of convertible notes.
• Commercial Launch Timeline: Monitor the Q1 2025 launch of ZUNVEYL and initial sales performance against the $649/month WAC pricing strategy.
• Derivative Liability Volatility: Review future filings for fluctuations in warrant and conversion feature liabilities, as these non-cash items significantly distort net loss figures.
• Related Party Transactions: Note the $1.21 million promissory note owed to Neurodyn Life Sciences Inc. (NLS) and the $2.27 million in shares issued to Spartan Capital for consulting services.
• Discontinued Assets: Confirm the status of the ALPHA-0602 technology, which was discontinued in Q3 2024, resulting in a $39,166 impairment charge.